Cargando…

Huangjia Ruangan Granule Inhibits Inflammation in a Rat Model with Liver Fibrosis by Regulating TNF/MAPK and NF-κB Signaling Pathways

The Huangjia Ruangan granule (HJRG) is a clinically effective Kampo formula, which has a significant effect on liver fibrosis and early liver cirrhosis. However, the mechanism underlying HJRG in treating liver fibrosis remains unclear. In this study, carbon tetrachloride (CCl(4)) was used to induce...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Qiang, Wang, Zongquan, Zhang, Rong, Zhang, Lili, Cui, Sainan, Lin, Huiyuan, Tang, Xinran, Yang, Dongying, Lin, Xianrong, Bai, Shasha, Gao, Jin, Yang, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356785/
https://www.ncbi.nlm.nih.gov/pubmed/35942372
http://dx.doi.org/10.1155/2022/8105306
_version_ 1784763593581920256
author Cai, Qiang
Wang, Zongquan
Zhang, Rong
Zhang, Lili
Cui, Sainan
Lin, Huiyuan
Tang, Xinran
Yang, Dongying
Lin, Xianrong
Bai, Shasha
Gao, Jin
Yang, Lei
author_facet Cai, Qiang
Wang, Zongquan
Zhang, Rong
Zhang, Lili
Cui, Sainan
Lin, Huiyuan
Tang, Xinran
Yang, Dongying
Lin, Xianrong
Bai, Shasha
Gao, Jin
Yang, Lei
author_sort Cai, Qiang
collection PubMed
description The Huangjia Ruangan granule (HJRG) is a clinically effective Kampo formula, which has a significant effect on liver fibrosis and early liver cirrhosis. However, the mechanism underlying HJRG in treating liver fibrosis remains unclear. In this study, carbon tetrachloride (CCl(4)) was used to induce liver fibrosis in rats to clarify the effect of HJRG on liver fibrosis and its mechanism. Using network pharmacology, the potential mechanism of HJRG was initially explored, and a variety of analyses were performed to verify this mechanism. In the liver fibrosis model, treatment with HJRG can maintain the liver morphology, lower the levels of AST and ALT in the serum, and ameliorate pathological damage. Histopathological examinations revealed that the liver structure was significantly improved and fibrotic changes were alleviated. It can effectively inhibit collagen deposition and the expression of α-SMA, reduce the levels of the rat serum (HA, LN, PC III, and Col IV), and inhibit the expression of desmin, vimentin, and HYP content in the liver. Analyzing the results of network pharmacology, the oxidative stress, inflammation, and the related pathways (primarily the TNF signaling pathway) were identified as the potential mechanism of HJRG against liver fibrosis. Experiments confirmed that HJRG can significantly increase the content of superoxide dismutase and glutathione and reduce the levels of malondialdehyde and myeloperoxidase in the rat liver; in addition, HJRG significantly inhibited the content of proinflammatory cytokines (TNF-α, IL-1β, and IL-6) and reduced the expression of inflammatory regulators (Cox2 and iNOS). Meanwhile, treatment with HJRG inhibited the phosphorylation of NF-κB P65, IκBα, ERK, JNK, and MAPK P38. Moreover, HJRG treatment reversed the increased expression of TNFR1. The Huangjia Ruangan granule can effectively inhibit liver fibrosis through antioxidation, suppressing liver inflammation by regulating the TNF/MAPK and NF-κB signaling pathways, thereby preventing the effect of liver fibrosis.
format Online
Article
Text
id pubmed-9356785
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-93567852022-08-07 Huangjia Ruangan Granule Inhibits Inflammation in a Rat Model with Liver Fibrosis by Regulating TNF/MAPK and NF-κB Signaling Pathways Cai, Qiang Wang, Zongquan Zhang, Rong Zhang, Lili Cui, Sainan Lin, Huiyuan Tang, Xinran Yang, Dongying Lin, Xianrong Bai, Shasha Gao, Jin Yang, Lei Evid Based Complement Alternat Med Research Article The Huangjia Ruangan granule (HJRG) is a clinically effective Kampo formula, which has a significant effect on liver fibrosis and early liver cirrhosis. However, the mechanism underlying HJRG in treating liver fibrosis remains unclear. In this study, carbon tetrachloride (CCl(4)) was used to induce liver fibrosis in rats to clarify the effect of HJRG on liver fibrosis and its mechanism. Using network pharmacology, the potential mechanism of HJRG was initially explored, and a variety of analyses were performed to verify this mechanism. In the liver fibrosis model, treatment with HJRG can maintain the liver morphology, lower the levels of AST and ALT in the serum, and ameliorate pathological damage. Histopathological examinations revealed that the liver structure was significantly improved and fibrotic changes were alleviated. It can effectively inhibit collagen deposition and the expression of α-SMA, reduce the levels of the rat serum (HA, LN, PC III, and Col IV), and inhibit the expression of desmin, vimentin, and HYP content in the liver. Analyzing the results of network pharmacology, the oxidative stress, inflammation, and the related pathways (primarily the TNF signaling pathway) were identified as the potential mechanism of HJRG against liver fibrosis. Experiments confirmed that HJRG can significantly increase the content of superoxide dismutase and glutathione and reduce the levels of malondialdehyde and myeloperoxidase in the rat liver; in addition, HJRG significantly inhibited the content of proinflammatory cytokines (TNF-α, IL-1β, and IL-6) and reduced the expression of inflammatory regulators (Cox2 and iNOS). Meanwhile, treatment with HJRG inhibited the phosphorylation of NF-κB P65, IκBα, ERK, JNK, and MAPK P38. Moreover, HJRG treatment reversed the increased expression of TNFR1. The Huangjia Ruangan granule can effectively inhibit liver fibrosis through antioxidation, suppressing liver inflammation by regulating the TNF/MAPK and NF-κB signaling pathways, thereby preventing the effect of liver fibrosis. Hindawi 2022-07-30 /pmc/articles/PMC9356785/ /pubmed/35942372 http://dx.doi.org/10.1155/2022/8105306 Text en Copyright © 2022 Qiang Cai et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Cai, Qiang
Wang, Zongquan
Zhang, Rong
Zhang, Lili
Cui, Sainan
Lin, Huiyuan
Tang, Xinran
Yang, Dongying
Lin, Xianrong
Bai, Shasha
Gao, Jin
Yang, Lei
Huangjia Ruangan Granule Inhibits Inflammation in a Rat Model with Liver Fibrosis by Regulating TNF/MAPK and NF-κB Signaling Pathways
title Huangjia Ruangan Granule Inhibits Inflammation in a Rat Model with Liver Fibrosis by Regulating TNF/MAPK and NF-κB Signaling Pathways
title_full Huangjia Ruangan Granule Inhibits Inflammation in a Rat Model with Liver Fibrosis by Regulating TNF/MAPK and NF-κB Signaling Pathways
title_fullStr Huangjia Ruangan Granule Inhibits Inflammation in a Rat Model with Liver Fibrosis by Regulating TNF/MAPK and NF-κB Signaling Pathways
title_full_unstemmed Huangjia Ruangan Granule Inhibits Inflammation in a Rat Model with Liver Fibrosis by Regulating TNF/MAPK and NF-κB Signaling Pathways
title_short Huangjia Ruangan Granule Inhibits Inflammation in a Rat Model with Liver Fibrosis by Regulating TNF/MAPK and NF-κB Signaling Pathways
title_sort huangjia ruangan granule inhibits inflammation in a rat model with liver fibrosis by regulating tnf/mapk and nf-κb signaling pathways
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356785/
https://www.ncbi.nlm.nih.gov/pubmed/35942372
http://dx.doi.org/10.1155/2022/8105306
work_keys_str_mv AT caiqiang huangjiaruangangranuleinhibitsinflammationinaratmodelwithliverfibrosisbyregulatingtnfmapkandnfkbsignalingpathways
AT wangzongquan huangjiaruangangranuleinhibitsinflammationinaratmodelwithliverfibrosisbyregulatingtnfmapkandnfkbsignalingpathways
AT zhangrong huangjiaruangangranuleinhibitsinflammationinaratmodelwithliverfibrosisbyregulatingtnfmapkandnfkbsignalingpathways
AT zhanglili huangjiaruangangranuleinhibitsinflammationinaratmodelwithliverfibrosisbyregulatingtnfmapkandnfkbsignalingpathways
AT cuisainan huangjiaruangangranuleinhibitsinflammationinaratmodelwithliverfibrosisbyregulatingtnfmapkandnfkbsignalingpathways
AT linhuiyuan huangjiaruangangranuleinhibitsinflammationinaratmodelwithliverfibrosisbyregulatingtnfmapkandnfkbsignalingpathways
AT tangxinran huangjiaruangangranuleinhibitsinflammationinaratmodelwithliverfibrosisbyregulatingtnfmapkandnfkbsignalingpathways
AT yangdongying huangjiaruangangranuleinhibitsinflammationinaratmodelwithliverfibrosisbyregulatingtnfmapkandnfkbsignalingpathways
AT linxianrong huangjiaruangangranuleinhibitsinflammationinaratmodelwithliverfibrosisbyregulatingtnfmapkandnfkbsignalingpathways
AT baishasha huangjiaruangangranuleinhibitsinflammationinaratmodelwithliverfibrosisbyregulatingtnfmapkandnfkbsignalingpathways
AT gaojin huangjiaruangangranuleinhibitsinflammationinaratmodelwithliverfibrosisbyregulatingtnfmapkandnfkbsignalingpathways
AT yanglei huangjiaruangangranuleinhibitsinflammationinaratmodelwithliverfibrosisbyregulatingtnfmapkandnfkbsignalingpathways